Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility, Efficacy And Safety Of De Novo Extended-Release Tacrolimus Following Liver Transplantation
NCT05242315Phase 4Recruiting
- Sponsor
- University of Alberta
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in Liver transplant rejection (2 arms), sponsored by University of Alberta. Primary endpoint: Safety of Envarsus as indicated by adverse events at 1 year. Started May 2022; status: recruiting.
02
Drugs
tacrolimus
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT05242315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242315.